Oxytocin
Main evidence: Small human studies. Updated 2026-10-28.
What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.
Summary
Oxytocin is an endogenous peptide hormone and an Australian-registered injectable medicine for specific obstetric care. Small intranasal laboratory studies do not establish general benefits for mood, relationships, sexual performance, exercise, or wellness. The reviewed evidence does not support self-use or a peptide-stack protocol.
What the sources say
- The Australian Syntocinon product information lists induction or augmentation of labour, management of the third stage of labour, and postpartum haemorrhage as indications; it is not a general enhancement medicine. (Manufacturer information; Syntocinon (oxytocin) solution for injection, Australian Product Information; MIMS revision date 2025-04-01, 2025-04-01)
- The TGA ARTG lists Syntocinon as an oxytocin injection ampoule with active licence status. This supports Australian registration of the injectable presentation, not a registered intranasal presentation. (Educator material (not peer reviewed); Therapeutic Goods Administration, SYNTOCINON oxytocin injection ampoule (ARTG 425470), public ARTG record checked 2026-10-28, 2026-10-28)
- The systematic review found no reliable excess of short-term subjective side effects versus placebo in controlled research, but its included evidence does not establish long-term safety for unsupervised use. (Small human studies; MacDonald et al., "A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research", 2011-03-23)
- The Australian label warns that excessive uterine stimulation can cause foetal distress, asphyxia, or uterine rupture, and requires continuous observation by trained staff during labour use. It also warns of maternal water intoxication and hyponatraemia with prolonged exposure and large volumes of electrolyte-free fluid. (Manufacturer information; Syntocinon (oxytocin) solution for injection, Australian Product Information; MIMS revision date 2025-04-01, 2025-04-01)
- The label lists obstetric contraindications and cautions, including foetal distress, situations where vaginal delivery is contraindicated, hypersensitivity, and cardiovascular risk. These risks are specific to the clinical obstetric use described in the label. (Manufacturer information; Syntocinon (oxytocin) solution for injection, Australian Product Information; MIMS revision date 2025-04-01, 2025-04-01)
Sources
- Syntocinon (oxytocin) solution for injection, Australian Product Information; MIMS revision date 2025-04-01 (2025-04-01)
- Therapeutic Goods Administration, SYNTOCINON oxytocin injection ampoule (ARTG 425470), public ARTG record checked 2026-10-28 (2026-10-28)
- MacDonald et al., "A review of safety, side-effects and subjective reactions to intranasal oxytocin in human research" (2011-03-23)
Dosing, stacking and protocol details are not published here.